Study of TQB3473 tablets for adults with chronic immune thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with primary ITP for at least 12 months.
- Your platelet counts have been consistently low (under 30,000) over the past 3 months, and you've had no severe bleeding in the last 4 weeks.
- You have tried glucocorticoids and at least one other standard ITP therapy that didn't work or stopped working.
- You are willing to use effective contraception during the study and for 6 months after treatment ends (if applicable).
- You have not had certain other medical conditions like uncontrolled infections, other cancers, or blood disorders that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet called TQB3473 for adults with persistent or long-lasting primary ITP. It is for people whose platelet counts stay low despite past treatments, and aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
This trial tests if a new medicine called QL0911 can help children with chronic ITP who haven't improved with standard treatments. It aims to raise platelet counts and reduce bleeding risk.
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.